Search Results
Your search for ,CNs matches 928 pages
Showing 801 - 850Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia
In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...
Telotristat Etiprate Shows Clinical Benefit in Treating Carcinoid Syndrome in Cancer Patients When Added to Standard of Care
Lexicon Pharmaceuticals, Inc's telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study presented...
ASTRO 2015: Pediatric Patients With Ependymoma Have Favorable Outcomes With Immediate Postsurgical Radiation Therapy
Outcomes for pediatric patients as young as 12 months old with ependymoma who are treated with immediate postoperative radiation therapy are favorable and consistent, based upon tumor surgical resection and tumor grade, according to research presented by Merchant et al (Abstract 1) on October...
ASTRO 2015: Patients With Intermediate-Risk Meningiomas Who Receive Postoperative Radiotherapy Have a 96% 3-Year Progression-Free Survival
Patients with intermediate meningiomas treated with radiation therapy after surgery experienced a 96% 3-year progression-free survival rate and had minimal adverse events, according to research presented by Rogers et al October 21, 2015, at the American Society for Radiation Oncology’s...
Targeted Chemotherapy Shows Early Signs of Slowing Neuroblastoma Tumor Growth With Less Toxicity in Preclinical Models
Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself, mainly because of the toxic effects of chemotherapy. But a team of surgeons is in the nascent stages of developing a more targeted, less toxic method of treating neuroblastoma patients with chemotherapy....
No Difference in Outcomes With Short-Course vs Longer-Course Radiotherapy in Elderly or Frail Patients With Newly Diagnosed Glioblastoma
In a noninferiority phase III trial reported in the Journal of Clinical Oncology, Roa et al found no difference in overall survival, progression-free survival, or quality of life between short-course and longer-course radiotherapy in elderly or frail patients with newly diagnosed glioblastoma...
FDA Approves Expanded Indication for Medical Device to Treat Newly Diagnosed Glioblastoma Multiforme
The U.S. Food and Drug Administration (FDA) today approved an expanded indication for the Optune tumor treating fields device to treat patients with newly diagnosed glioblastoma multiforme. It is given along with the chemotherapy drug temozolomide following standard treatments that include...
ECC 2015: Lung and Gastrointestinal Neuroendocrine Tumors and Results From the RADIANT-4 Trial
An international team of researchers has shown that the use of the mTOR inhibitor everolimus can delay tumor growth among both gastrointestinal and lung neuroendocrine tumors. This is particularly important for patients with lung tumors, the researchers say, because there is currently no approved...
ECC 2015: Advanced Gastrointestinal Neuroendocrine Tumors and Results From the NETTER-1 Trial
Results from a multicenter randomized international trial of an innovative treatment show a marked improvement in the length of time patients with midgut neuroendocrine tumors experience progression-free survival, researchers reported at the 2015 European Cancer Congressin Vienna, Austria, on...
ECC 2015: Genetic Screening of Brain Metastases Could Reveal New Targets for Treatment
Unraveling the genetic sequences of cancer that has spread to the brain could offer unexpected targets for effective treatment, according to new research (Abstract 2905) presented at the 2015 European Cancer Congress in Vienna, Austria, and published simultaneously by Brastianos et al in...
Long-Term Infusion of Immunotherapy May Reduce Pain in Children With High-Risk Neuroblastoma
Changing the infusion delivery method of the monoclonal antibody ch14.18/CHO (dinutuximab-beta, the European counterpart of dinutuximab [Unituxin]) in combination with interleukin-2 and oral 13-cis-retinoic acid from short-term infusion to long-term infusion in the treatment of children with...
FDA Grants Alectinib Priority Review for ALK‑Positive Lung Cancer
Genentech announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive,...
Combination of Chemotherapy and T-Cell Immunotherapy May Provide Novel Treatment Strategy for Glioblastoma
A preclinical study has found that a combination of decitabine and T-cell immunotherapy demonstrated antitumor activity against glioblastomas in mouse models and was about 50% effective at curing the disease. The results, reported by Everson et al in Neuro-Oncology, show an innovative,...
Complete Resection of High-Grade Gliomas Yields Better Survival in Children, Especially Girls
For children with aggressive brain cancers called high-grade gliomas, the chances of survival are improved when surgery is successful in eliminating all visible cancer, according to a report published by McCrea et al in Neurosurgery. In addition to showing better survival with gross total...
Study Reveals Effects of Chemoradiation in Brains of Glioblastoma Patients
A study from Massachusetts General Hospital (MGH) Cancer Center researchers—the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients—revealed not only specific structural changes within patients’ brains, but also...
Medullablastomas Can Be Classified Noninvasively at Diagnosis
Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups, each with a different risk profile requiring subgroup-specific therapy. Currently, subgroup determination is done after surgical removal of the tumor. Investigators at...
Psychosocial and Neurocognitive Impairment in Adult Survivors of Adolescent and Young Adult Cancer
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Prasad et al found evidence of impaired psychosocial and neurocognitive function among long-term cancer survivors diagnosed during adolescence and young adulthood. Risk of Impairment In the...
Noninvasive Prenatal Testing May Also Detect Some Maternal Cancers
A study published by Bianchi et al in the Journal of the American Medical Association (JAMA) showed that genetic test results revealed by noninvasive prenatal testing for fetal chromosomal abnormalities may detect underlying conditions in the mother, including cancer. The study reports on a case...
FDA Grants Orphan Drug Designation to Anti‑Tropomyosin Drug for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Novogen Limited’s chemotherapy candidate drug Anisina for neuroblastoma. Anisina is a small molecule belonging to a family of compounds called anti-tropomyosins. It has been designed to inhibit Tpm3.1, a...
Early Study Suggests Which Glioblastoma Patients May Benefit From Dasatinib
Clinicians testing the drug dasatinib (Sprycel), approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical...
Molecular Classification of Glioma Based on IDH Mutation, 1p/19q Codeletion, and TERT Promoter Mutation Status
In a study reported in The New England Journal of Medicine, Eckel-Passow et al identified a molecular classification scheme for gliomas based on IDH mutation, codeletion of chromosome arms 1p and 19q (1p/19q codeletion), and TERT promoter mutation status. Molecular Classification The study...
ASCO 2015: Gene Therapy Paired With Traditional Surgical Resection Benefits Patients With Glioblastoma
Houston Methodist Neurological Institute neurosurgeon David Baskin, MD, presented preliminary data from a phase II clinical trial that suggests gene therapy (AdV-Tk therapy), which uses a mediated herpes simplex virus, combined with a traditional treatment—surgical resection—could ...
Assay Permits Rapid Molecular Characterization of Glioma
As reported in JAMA Oncology, Shankar et al developed a rapid genotyping assay to detect single nucleotide variants in telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1) genes that may assist in intraoperative decisions to perform definitive neurosurgical...
Multicenter Study Redefines Brain Tumor Diagnosis and Treatment
Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated. The study, a project of The Cancer Genome Atlas, found striking molecular differences between various forms of gliomas by looking at the makeup ...
ASCO 2015: Glioblastoma Poliovirus Therapy Works Best at a Low Dosage
A modified poliovirus therapy that is showing activity in patients with glioblastoma works best at a low dosage, according to the research team at Duke’s Preston Robert Tisch Brain Tumor Center. The dosage findings for the first 20 patients in the phase 1 trial were presented June 1 at the...
ASCO 2015: Study Supports IDH Gene as Prognostic Marker in Anaplastic Astrocytoma
New findings from a phase III clinical trial suggest the IDH1 gene may be a prognostic marker for anaplastic astrocytoma, a rare form of brain cancer. The results of this study were presented on June 2 at the 2015 ASCO Annual Meeting in Chicago (Abstract 2002). Patients in this study who had a...
Addition of Bevacizumab to Radiotherapy and Temozolomide Does Not Worsen Health-Related Quality of Life in Glioblastoma Patients
In the phase III AVAglio trial, the addition of bevacizumab (Avastin) to radiotherapy and temozolomide improved progression-free survival in patients with newly diagnosed glioblastoma. As reported by Taphoorn et al in the Journal of Clinical Oncology, bevacizumab treatment did not worsen...
Blood Thinners Safe for Cancer Patients With Brain Metastases
Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study published by Donato et al in Blood. Cancer increases a patient’s risk of developing blood clots, and an anticoagulant is often...
Preclinical Study Points to Possible Treatment for Lethal Pediatric Brain Cancer
Using brain tumor samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat (Farydak) and similar gene-regulating drugs may be effective at treating diffuse intrinsic pontine glioma (DIPG), an aggressive and lethal form of...
Donepezil Provides Modest Improvement in Cognitive Function Domains in Irradiated Brain Tumor Survivors
In a phase III trial reported in the Journal of Clinical Oncology, Rapp et al found that the neurotransmitter modulator donepezil may modestly improve some cognitive function domains in patients undergoing cranial irradiation for brain tumors. Improvements were greater in patients with greater...
Study Recommends Brain Cancer Patients Be Screened for Depression
Depression in brain cancer patients is a common but often overlooked condition, and oncologists should regularly screen tumor patients for depression, according to an article by Pranckeviciene and Bunevicius in CNS Oncology. The authors, both of the Lithuanian University of Health Sciences,...
Preliminary Study Reveals Gene Regulatory Path as Target for Aggressive Pediatric Brain Cancer
Working with cells taken from children with a very rare but aggressive form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of genes, and may spur cancer cell growth and resistance to anticancer treatment. ...
NIH-Funded Study Suggests Novel Strategy to Improve Vaccine Efficacy in the Treatment of Glioblastoma
Although dendritic cell–based immunotherapy has shown limited promise in the treatment of patients with advanced cancers, including glioblastoma, the factors dictating dendritic cell–based vaccine efficacy have been poorly understood. Now, a clinical trial funded by the National...
Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma Defined by BRAF Mutation and CDKN2A Deletion
In a study reported in the Journal of Clinical Oncology, Mistry et al found that presence of BRAF V600E mutation and CDKN2A deletion defined a clinically distinct subtype of pediatric secondary high-grade glioma. BRAF V600E mutation was associated with a prolonged time to transformation. Study...
Clinical Trial Suggests Temozolomide-Based Chemoradiation Is Best for Low-Grade Brain Tumors
New clinical trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer...
Similar Local Recurrence Rates But Increased Distant Metastases With Adjuvant Localized vs Whole-Brain Radiotherapy in Patients With Brain Metastases
In patients who had undergone surgery for brain metastases, the rate of recurrence at the resected site was similar between patients who received adjuvant whole-brain radiotherapy vs those who underwent adjuvant localized radiotherapy, according to a retrospective study by Hsieh et al in the...
FDA Approves Dinutuximab Combination for Pediatric Patients With High-Risk Neuroblastoma
The U.S. Food and Drug Administration has approved dinutuximab (Unituxin) as part of first-line therapy for pediatric patients with high-risk neuroblastoma. Dinutuximab, a chimeric monoclonal antibody that binds to the surface of neuroblastoma cells, is being approved for use as part of a...
Preclinical Study Shows Promise for the Development of Personalized Cellular Therapy for Brain Cancer
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be safe and effective at controlling tumor growth in mice that were treated with these modified cells, according a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis...
Study Finds Improved Survival for Young Patients With Brain Metastases Who Receive Stereotactic Radiosurgery Alone
Cancer patients with limited brain metastases (one to four tumors) who are 50 years old and younger should receive stereotactic radiosurgery without whole-brain radiotherapy, according to a study by Saghal et al in the International Journal of Radiation Oncology • Biology • Physics....
Inconclusive Outcome for Lapatinib vs Trastuzumab Plus Capecitabine in Preventing CNS Metastases as First Relapse Site in HER2-Positive Breast Cancer
In the phase III CEREBEL study reported in the Journal of Clinical Oncology, Pivot et al compared lapatinib (Tykerb)-capecitabine vs trastuzumab (Herceptin)-capecitabine in the prevention of central nervous system (CNS) metastases as first relapse site in patients with metastatic HER2-positive...
Scientists Identify Genetic Variations Linked to Treatment-Related Hearing Loss in Young Patients With Cancer
Using a genome-wide associated study approach, researchers have identified inherited genetic variations in the ACYP2 gene that were linked to as much as a fourfold greater risk of rapid hearing loss in young patients with newly diagnosed brain tumors treated with cisplatin chemotherapy. The study...
Crizotinib Produces Systemic and Intracranial Disease Control in Patients With Advanced ALK-Rearranged NSCLC and Brain Metastases
In a retrospective analysis reported in the Journal of Clinical Oncology, Costa et al found that crizotinib (Xalkori) treatment resulted in high systemic and intracranial disease control rates in patients with ALK-rearranged non–small cell lung cancer (NSCLC) who had asymptomatic brain...
Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
Long-Term Use of Hormonal Contraceptives Could Lead to Increased Risk of Brain Tumors
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
FDA Approves Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) today approved lanreotide (Somatuline Depot Injection) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. Lanreotide was previously approved for...
Germline SUFU Mutations Cause Gorlin Syndrome and Increase Risk for Childhood Medulloblastoma
In a study to identify causative mutations in patients with Gorlin syndrome without PTCH1 mutations, Smith et al found that germline mutations in SUFU were associated with Gorlin syndrome and with increased likelihood of Gorlin syndrome–associated childhood medulloblastoma. The study is...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
Molecular Tumor Markers Could Reveal New Therapeutic Targets for Lung Cancer Treatment
Analysis of 607 small cell lung cancer (SCLC) tumors and neuroendocrine tumors identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented at the 2014 Chicago Multidisciplinary...
FDA Grants Orphan Drug Designation to DNX-2401 for Malignant Glioma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DNAtrix’s DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical...
